Reading Time: 2 minutesSpeaking at TD Cowen’s September 26th panel, Advancement in Psychedelic Therapies for Neuropsychiatry, execs from atai Life Sciences, Cybin, and GH
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minuteIn this Issue atai Sells a Third of Compass Stake to Raise Cash for In-House
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minuteatai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 (Mar 4)
Reading Time: < 1 minuteIn this Issue Upcoming Trial Readouts to Watch Lykos Prioritises Preparing for Resubmission Over Formal
Reading Time: 8 minutesJuly 12th: NMAB Combined Subcommittee MeetingThe July 12th meeting of the combined subcommittee began with
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minuteIn this Issue Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla Lykos
Reading Time: 2 minutesFollowing Lykos Therapeutics’ receipt of a Complete Response Letter (CRL) from the FDA, which is effectively a rejection of